MorphoSys AG, DE0006632003

MorphoSys AG, DE0006632003

18.05.2018 - 14:32:23

MorphoSys to Present at Upcoming Investor Conferences

Planegg/Munich, Germany, May 18, 2018

MorphoSys to Present at Upcoming Investor Conferences

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) will present at the following conferences:  

UBS Global Healthcare Conference Date: May 21, 2018, 11:00 am EDT (5:00 pm CEST, 4:00 pm BST) Venue: New York, NY, US Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG Dr. Claudia Gutjahr-Löser, Investor Relations Officer  

Berenberg European Conference USA Date: May 22, 2018 Venue: Tarrytown, NY, US Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG Dr. Claudia Gutjahr-Löser, Investor Relations Officer  

PDF versions of the presentations will be provided at www.morphosys.com. The link to the webcasts will be filed under www.morphosys.com/conference-calls.  

About MorphoSys MorphoSys is a late-stage, biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Based on its technological leadership in generating antibodies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. This broad pipeline spans MorphoSys's two business segments: Proprietary Development, in which MorphoSys invests in product candidates for its own account, and Partnered Discovery, in which product candidates are developed exclusively for a variety of Pharma and Biotech partners. In 2017, Tremfya(R) (guselkumab), marketed by Janssen, became the first therapeutic antibody based on MorphoSys's proprietary technology to receive marketing approval for the treatment of moderate-to-severe plaque psoriasis in the United States, the European Union and Canada. MorphoSys is listed on the Frankfurt Stock Exchange and on the U.S. stock exchange Nasdaq, under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.  

MorphoSys forward looking statementsThis communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the commencement of the IGUANA trial in connection with MOR106 and expectations regarding the development of MOR106 in moderate-to-severe atopic dermatitis, including the intended targeting of IL-17C. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties and other risks indicated in the risk factors included in MorphoSys's Registration Statement on Form F-1 and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.  

For more information, please contact:

MorphoSys AG Alexandra Goller Associate Director Corporate Communications & IR

Jochen Orlowski Associate Director Corporate Communications & IR

Dr. Claudia Gutjahr-Löser Investor Relations Officer

Tel: +49 (0) 89 / 899 27-404 investors@morphosys.com

Additional features:Document: http://n.eqs.com/c/fncls.ssp?u=SJYDSGKTWBDocument title: Media Release

18.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg

Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: investors@morphosys.com Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

687735  18.05.2018 

@ dgap.de

Amazon wird sich schwarzärgern, aber …

… wir schenken Ihnen den Report „Börsenpsychologie - Markttechnik für Trader“ heute trotzdem kostenfrei. Normalerweise kostet der Report im Onlinehandel 39,99 Euro.

Sie können sich den genialen Report heute jedoch absolut kostenfrei sichern. Wir senden Ihnen den Report vollkommen KOSTENFREI zu.

Jetzt HIER klicken und dank richtigen Timing reich an der Börse werden!